Results 51 to 60 of about 20,284 (182)

Pharmacogenomics of Major Depressive Disorder in Indigenous Amazonian Populations

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder is a highly prevalent psychological disorder worldwide and its main treatment is the use of Selective Serotonin Reuptake Inhibitors. However, few studies have demonstrated the relationship between the presence of genetic variants in pharmacogenes and the efficacy of these drugs, especially in populations with a unique genetic ...
Kaio Evandro Cardoso Aguiar, Natasha Monte da Silva, Juliana Carla Gomes Rodrigues, André Maurício Ribeiro‐dos‐Santos, Sandro José de Souza, Ândrea Ribeiro‐dos‐Santos, João Farias Guerreiro, Sidney Emanuel Batista dos Santos, Marianne Rodrigues Fernandes, Ney Pereira Carneiro dos Santos   +9 more
wiley   +1 more source

Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease

ARYA Atherosclerosis, 2011
BACKGROUND: The polymorphisms of cytochrome P450 2C19 (CYP2C19) gene are major prognostic factors for the response to clopidogrel therapy in patients with coronary artery diseases (CAD).
Arash Akhlaghi, Shahin Shirani, Naghmeh Ziaie, Omid Pirhaji, Majid Yaran, Golnoosh Shahverdi, Nizal Sarrafzadegan, Alireza khosravi, Elham khosravi   +8 more
doaj  

CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt

Journal of Epidemiology and Global Health, 2023
Background Cardiovascular diseases (CVDs) are considered a leading cause of death worldwide. Allelic variation in the CYP2C19 gene leads to a dysfunctional enzyme, and patients with this loss-of-function allele will have an impaired clopidogrel ...
Ahmed Shawky, Hussein Sabit, Mahmoud Nazih, Khalid Baraka, Mokhtar El-Zawahry   +4 more
doaj   +1 more source

Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults

Clinical Pharmacology &Therapeutics, EarlyView.
Cannabidiol (CBD) is one of the most abundant bioactive cannabinoids. Research has demonstrated CBD’s ability to inhibit metabolic enzymes like cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT), potentially leading to drug interactions. However, clinical knowledge gaps remain, particularly with regard to drugs that are more commonly taken by ...
Pablo Salcedo, Donna A. Volpe, Anik Chaturbedi, Aanchal Shah, Ashok Krishna, Paula L Hyland, Giri Vegesna, Cheng‐Hui Hsiao, Ryan De Palma, Melanie Fein, Rodney Rouse, Jeffry Florian   +11 more
wiley   +1 more source

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes, Henry Fong, Grace Hampson, Catrin O. Plumpton, Chris Sampson   +4 more
wiley   +1 more source

Unveiling Hepatic Protein Alterations in Neonatal and Infant Biliary Atresia

Clinical Pharmacology &Therapeutics, EarlyView.
Pediatric populations differ from adults in drug elimination capacity. While current scaling methods account for enzyme and transporter maturation, they overlook comorbidities, such as biliary atresia (BA), a liver disease appearing within the first 2–8 weeks of life that can progress to cirrhosis.
Zubida M. Al‐Majdoub, Martyn Howard, Brahim Achour, Jill Barber, Naved Alizai, Amin Rostami‐Hodjegan   +5 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

ASSESSMENT OF THE CLOPIDOGREL ACTION WITH REGARD TO CYP2C19 GENE POLYMORPHISMS IN PATIENTS WITH CORONARY ARTERY DISEASE AFTER IMPLANTATION OF DES STENTS

Евразийский Кардиологический Журнал, 2019
Aim of the work to assess the impact of CYP2C19 polymorphisms, including those of CYP2C19*1, CYP2C19*2, CYP2C19*3 and CYP2C19*17 on clopidogrel response variability in patients undergoing percutaneous coronary intervention (PCI) following DES ...
J. K. Uzokov, B. A. Alyavi, A. X. Abdullaev   +2 more
doaj  

A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel

Scientific Reports
CYP2C19 gene has multiple single nucleotide polymorphism (SNP), which is the major determinant for clopidogrel treatment responses. Therefore, CYP2C19 SNP detection is essential for predicting clopidogrel efficacy.
Hongwei Li, Yizhen Fang, Yongquan Chen, Yuning Lin, Zanxi Fang, Zhiyuan Lin, Huabin Xie, Zhongying Zhang   +7 more
doaj   +1 more source

Polymorphisms of MDR1, CYP2C19 and P2Y12 genes in Indian population: Effects on clopidogrel response

Indian Heart Journal, 2013
Aims/objective: Influence of genetic variations on the response of clopidogrel, an antiplatelet drug is implicated. In the present study, the prevalence of single nucleotide polymorphisms of MDR1 (C3435T), CYP2C19 [CYP2C19*2 CYP2C19*3, CYP2C19*17] and ...
Kavita K. Shalia, Vinod K. Shah, Poonam Pawar, Siddhi S. Divekar, Satchidanand Payannavar   +4 more
doaj   +1 more source